What is Noble Financial’s Estimate for NRSN FY2025 Earnings?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) – Stock analysts at Noble Financial issued their FY2025 earnings per share (EPS) estimates for shares of NeuroSense Therapeutics in a research note issued to investors on Tuesday, October 14th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of ($0.40) for the year. Noble Financial currently has a “Strong-Buy” rating on the stock. Noble Financial also issued estimates for NeuroSense Therapeutics’ FY2026 earnings at ($0.37) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at ($0.11) EPS and FY2029 earnings at $1.65 EPS.

Several other equities analysts have also recently issued reports on NRSN. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research report on Wednesday, October 8th. D. Boral Capital restated a “buy” rating and issued a $14.00 target price on shares of NeuroSense Therapeutics in a report on Friday, August 15th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, NeuroSense Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $14.00.

NeuroSense Therapeutics Stock Performance

Shares of NRSN stock opened at $1.22 on Thursday. NeuroSense Therapeutics has a 1 year low of $0.80 and a 1 year high of $2.60. The stock has a market cap of $16.95 million, a PE ratio of -2.26 and a beta of 1.61. The business’s fifty day moving average is $1.19 and its 200-day moving average is $1.43.

Hedge Funds Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Jane Street Group LLC bought a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 28,689 shares of the company’s stock, valued at approximately $54,000. Jane Street Group LLC owned about 0.21% of NeuroSense Therapeutics as of its most recent SEC filing. 1.04% of the stock is currently owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.